BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fernández Massó JR, Oliva Argüelles B, Tejeda Y, Astrada S, Garay H, Reyes O, Delgado-Roche L, Bollati-Fogolín M, Vallespí MG. The Antitumor Peptide CIGB-552 Increases COMMD1 and Inhibits Growth of Human Lung Cancer Cells. J Amino Acids 2013;2013:251398. [PMID: 23401744 DOI: 10.1155/2013/251398] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Rodríguez-Ulloa A, Gil J, Ramos Y, Hernández-Álvarez L, Flores L, Oliva B, García D, Sánchez-Puente A, Musacchio-Lasa A, Fernández-de-Cossio J, Padrón G, González López LJ, Besada V, Guerra-Vallespí M. Proteomic Study to Survey the CIGB-552 Antitumor Effect. Biomed Res Int 2015;2015:124082. [PMID: 26576414 DOI: 10.1155/2015/124082] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
2 Astrada S, Fernández Massó JR, Vallespí MG, Bollati-Fogolín M. Cell Penetrating Capacity and Internalization Mechanisms Used by the Synthetic Peptide CIGB-552 and Its Relationship with Tumor Cell Line Sensitivity. Molecules 2018;23:E801. [PMID: 29601540 DOI: 10.3390/molecules23040801] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
3 Daghero H, Pagotto R, Vallespí MG, Bollati-fogolín M. Generation of stable reporter breast and lung cancer cell lines for NF-κB activation studies. Journal of Biotechnology 2019;301:79-87. [DOI: 10.1016/j.jbiotec.2019.05.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Wang X, He S, Zheng X, Huang S, Chen H, Chen H, Luo W, Guo Z, He X, Zhao Q. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma. BMC Cancer 2021;21:1001. [PMID: 34493238 DOI: 10.1186/s12885-021-08699-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Esposito E, Napolitano G, Pescatore A, Calculli G, Incoronato MR, Leonardi A, Ursini MV. COMMD7 as a novel NEMO interacting protein involved in the termination of NF-κB signaling. J Cell Physiol 2016;231:152-61. [PMID: 26060140 DOI: 10.1002/jcp.25066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
6 Astrada S, Gomez Y, Barrera E, Obal G, Pritsch O, Pantano S, Vallespí MG, Bollati-Fogolín M. Comparative analysis reveals amino acids critical for anticancer activity of peptide CIGB-552. J Pept Sci 2016;22:711-22. [PMID: 27933724 DOI: 10.1002/psc.2934] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
7 Vallespi MG, Mestre B, Marrero MA, Uranga R, Rey D, Lugiollo M, Betancourt M, Silva K, Corrales D, Lamadrid Y, Rodriguez Y, Maceo A, Chaviano PP, Lemos G, Cabrales A, Freyre FM, Santana H, Garay HE, Oliva B, Fernandez JR. A first-in-class, first-in-human, phase I trial of CIGB-552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF-κB in patients with advanced solid tumors. Int J Cancer 2021;149:1313-21. [PMID: 34019700 DOI: 10.1002/ijc.33695] [Reference Citation Analysis]
8 Daghero H, Fernández Massó JR, Astrada S, Guerra Vallespí M, Bollati-Fogolín M. The Anticancer Peptide CIGB-552 Exerts Anti-Inflammatory and Anti-Angiogenic Effects through COMMD1. Molecules 2020;26:E152. [PMID: 33396282 DOI: 10.3390/molecules26010152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Fedoseienko A, Wieringa HW, Wisman GB, Duiker E, Reyners AK, Hofker MH, van der Zee AG, van de Sluis B, van Vugt MA. Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. PLoS One 2016;11:e0165385. [PMID: 27788210 DOI: 10.1371/journal.pone.0165385] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
10 Yang M, Huang W, Sun Y, Liang H, Chen M, Wu X, Wang X, Zhang L, Cheng X, Fan Y, Pan H, Chen L, Guan J. Prognosis and modulation mechanisms of COMMD6 in human tumours based on expression profiling and comprehensive bioinformatics analysis. Br J Cancer 2019;121:699-709. [PMID: 31523056 DOI: 10.1038/s41416-019-0571-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
11 Han J, Jing Y, Han F, Sun P. Comprehensive analysis of expression, prognosis and immune infiltration for TIMPs in glioblastoma. BMC Neurol 2021;21:447. [PMID: 34781885 DOI: 10.1186/s12883-021-02477-1] [Reference Citation Analysis]
12 Vallespí MG, Pimentel G, Cabrales-rico A, Garza J, Oliva B, Mendoza O, Gomez Y, Basaco T, Sánchez I, Calderón C, Rodriguez JC, Markelova MR, Fichtner I, Astrada S, Bollati-fogolín M, Garay HE, Reyes O. Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models: ANTITUMOR EFFICACY, PHARMACOKINETIC AND BIODISTRIBUTION STUDIES OF CIGB-552. J Pept Sci 2014;20:850-9. [DOI: 10.1002/psc.2676] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
13 Oliva Arguelles B, Riera-Romo M, Guerra Vallespi M. Antitumour peptide based on a protein derived from the horseshoe crab: CIGB-552 a promising candidate for cancer therapy. Br J Pharmacol 2020;177:3625-34. [PMID: 32436254 DOI: 10.1111/bph.15132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Núñez de Villavicencio-díaz T, Ramos Gómez Y, Oliva Argüelles B, Fernández Masso JR, Rodríguez-ulloa A, Cruz García Y, Guirola-cruz O, Perez-riverol Y, Javier González L, Tiscornia I, Victoria S, Bollati-fogolín M, Besada Pérez V, Guerra Vallespi M. Comparative proteomics analysis of the antitumor effect of CIGB-552 peptide in HT-29 colon adenocarcinoma cells. Journal of Proteomics 2015;126:163-71. [DOI: 10.1016/j.jprot.2015.05.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
15 Lugo JM, Tafalla C, Oliva A, Pons T, Oliva B, Aquilino C, Morales R, Estrada MP. Evidence for antimicrobial and anticancer activity of pituitary adenylate cyclase-activating polypeptide (PACAP) from North African catfish (Clarias gariepinus): Its potential use as novel therapeutic agent in fish and humans. Fish & Shellfish Immunology 2019;86:559-70. [DOI: 10.1016/j.fsi.2018.11.056] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
16 Zheng L, You N, Huang X, Gu H, Wu K, Mi N, Li J. COMMD7 Regulates NF-κB Signaling Pathway in Hepatocellular Carcinoma Stem-like Cells. Mol Ther Oncolytics 2019;12:112-23. [PMID: 30719501 DOI: 10.1016/j.omto.2018.12.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
17 Suraweera A, Duijf PHG, Jekimovs C, Schrobback K, Liu C, Adams MN, O'Byrne KJ, Richard DJ. COMMD1, from the Repair of DNA Double Strand Breaks, to a Novel Anti-Cancer Therapeutic Target. Cancers (Basel) 2021;13:830. [PMID: 33669398 DOI: 10.3390/cancers13040830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Campion CG, Verissimo T, Cossette S, Tremblay J. Does Subtelomeric Position of COMMD5 Influence Cancer Progression? Front Oncol 2021;11:642130. [PMID: 33768002 DOI: 10.3389/fonc.2021.642130] [Reference Citation Analysis]